2021
Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps
Chen B, Scurrah CR, McKinley ET, Simmons AJ, Ramirez-Solano MA, Zhu X, Markham NO, Heiser CN, Vega PN, Rolong A, Kim H, Sheng Q, Drewes JL, Zhou Y, Southard-Smith AN, Xu Y, Ro J, Jones AL, Revetta F, Berry LD, Niitsu H, Islam M, Pelka K, Hofree M, Chen JH, Sarkizova S, Ng K, Giannakis M, Boland GM, Aguirre AJ, Anderson AC, Rozenblatt-Rosen O, Regev A, Hacohen N, Kawasaki K, Sato T, Goettel JA, Grady WM, Zheng W, Washington MK, Cai Q, Sears CL, Goldenring JR, Franklin JL, Su T, Huh WJ, Vandekar S, Roland JT, Liu Q, Coffey RJ, Shrubsole MJ, Lau KS. Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell 2021, 184: 6262-6280.e26. PMID: 34910928, PMCID: PMC8941949, DOI: 10.1016/j.cell.2021.11.031.Peer-Reviewed Original ResearchMeSH KeywordsAdaptive ImmunityAdenomaAdultAgedAnimalsCarcinogenesisCell DeathCell DifferentiationColonic PolypsColorectal NeoplasmsDisease ProgressionFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksGenetic HeterogeneityHumansMaleMiceMiddle AgedMutationNeoplastic Stem CellsReproducibility of ResultsRNA-SeqSingle-Cell AnalysisTumor MicroenvironmentConceptsHuman colorectal polypsColorectal cancerColorectal polypsPrevention of CRCMicrosatellite-unstable colorectal cancersUnstable colorectal cancersGastric metaplasiaImmune microenvironmentTumor cell differentiation statusImmune cellsPrecision surveillancePrecursor polypsSerrated polypsConventional adenomasStem cell propertiesMalignant progressionImmunogenic potentialPolypsTumor cellsTherapeutic insightsCell differentiation statusCellular originMetaplasiaAdenomasMolecular heterogeneity
2011
Tamoxifen Induces Rapid, Reversible Atrophy, and Metaplasia in Mouse Stomach
Huh WJ, Khurana SS, Geahlen JH, Kohli K, Waller RA, Mills JC. Tamoxifen Induces Rapid, Reversible Atrophy, and Metaplasia in Mouse Stomach. Gastroenterology 2011, 142: 21-24.e7. PMID: 22001866, PMCID: PMC3708546, DOI: 10.1053/j.gastro.2011.09.050.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnimalsAtrophyChief Cells, GastricFemaleGene Expression RegulationInjections, IntraperitonealIntegrasesLac OperonMaleMetaplasiaMiceMice, Inbred BALB CMice, Inbred C57BLMice, TransgenicParietal Cells, GastricSelective Estrogen Receptor ModulatorsSpecies SpecificityTamoxifenTime FactorsConceptsSelective estrogen receptor modulatorsParietal cellsBody weight doseEstrogen receptor modulatorsTamoxifen side effectsAcid secretion inhibitionZymogenic chief cellsReversible atrophyWeight doseGastric toxicityIntraperitoneal administrationReceptor modulatorsNormal miceSide effectsSecretion inhibitionGastric parietal cellsChief cellsMouse stomachTamoxifenMetaplasiaMultiple strainsToxicityCellsPatientsAtrophy
2010
The Transcription Factor MIST1 Is a Novel Human Gastric Chief Cell Marker Whose Expression Is Lost in Metaplasia, Dysplasia, and Carcinoma
Lennerz JK, Kim SH, Oates EL, Huh WJ, Doherty JM, Tian X, Bredemeyer AJ, Goldenring JR, Lauwers GY, Shin YK, Mills JC. The Transcription Factor MIST1 Is a Novel Human Gastric Chief Cell Marker Whose Expression Is Lost in Metaplasia, Dysplasia, and Carcinoma. American Journal Of Pathology 2010, 177: 1514-1533. PMID: 20709804, PMCID: PMC2928982, DOI: 10.2353/ajpath.2010.100328.Peer-Reviewed Original ResearchConceptsChief cellsTranscription factor MIST1Gastric carcinogenesisMIST1 expressionSimilar progressive lossChief cell lineagesNormal oxyntic mucosaHuman gastric carcinogenesisHuman chief cellsChief cell markersIntestinal metaplasiaCell carcinomaMetaplastic lesionsResection specimensGastric adenocarcinomaPrecursor lesionsOxyntic mucosaTissue microarrayMetaplasiaMurine dataReliable markerTFF2 expressionHuman lesionsCell markersComparison of findings